STEM-TECH

STEM-TECH: Introducing proprietary stem cell marker technology for the life sciences market

 Coordinatore UNIVERSITAIR MEDISCH CENTRUM UTRECHT 

Spiacenti, non ci sono informazioni su questo coordinatore. Contattare Fabio per maggiori infomrazioni, grazie.

 Nazionalità Coordinatore Netherlands [NL]
 Totale costo 163˙100 €
 EC contributo 148˙280 €
 Programma FP7-IDEAS-ERC
Specific programme: "Ideas" implementing the Seventh Framework Programme of the European Community for research, technological development and demonstration activities (2007 to 2013)
 Code Call ERC-2012-PoC
 Funding Scheme CSA-SA(POC)
 Anno di inizio 2013
 Periodo (anno-mese-giorno) 2013-02-01   -   2014-07-31

 Partecipanti

# participant  country  role  EC contrib. [€] 
1    UNIVERSITAIR MEDISCH CENTRUM UTRECHT

 Organization address address: HEIDELBERGLAAN 100
city: UTRECHT
postcode: 3584 CX

contact info
Titolo: Mr.
Nome: Joost
Cognome: Warsanis
Email: send email
Telefono: +31 88 7568064

NL (UTRECHT) hostInstitution 148˙280.00

Mappa


 Word cloud

Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.

opportunity    proprietary    market    cell    marker    business    area    detection    companies    stem    technologies    tech    cancer    clinical   

 Obiettivo del progetto (Objective)

'STEM-TECH has been designed to investigate the commercial opportunity for exploiting our patented stem cell marker technology in the life sciences market. This proprietary technology will meet the need for new enabling technologies that unlock the potential of stem cell detection in academic, industrial and clinical research and practice.

THE OPPORTUNITY The stem cell market is a relatively immature market with an estimated size of around EUR 1 billion in 2011. It is expected that the market for stem cell technologies will increase substantially, mainly because leading biopharmaceutical companies are showing considerable interest in this area. Next to the pharma industry, major suppliers and small companies are now developing a wide range of stem cell approaches, which reflects the interest in this emerging area. Companies like Invitrogen provide reagents and services for stem cell research.

THE PROJECT In STEM-TECH the central aim is to commercialise a (cancer) stem cell detection technology that can be used in intestinal, skin, breast and brain (cancer) stem cell research for (not exhaustive): - Fundamental and applied research purposes, e.g. the study of stem cell behaviour or signaling in and ex vivo; - The development of clinical detection methods (diagnostics) for determining disease status and metastasis; - The development of treatments that are specifically targeted at cancer stem cells.

THE FINAL GOAL In a 12 month project, the skilled team of STEM-TECH will analyse the business potential of the proprietary stem cell marker technology. Within this project we will validate the technology to increase value, conduct a detailed market research, file and define the IP stratetgy and develop a full fledged business plan. The path that results in the highest ratio of return over effort will be used for commercialization.'

Altri progetti dello stesso programma (FP7-IDEAS-ERC)

SUBJECTPENAL (2012)

"Subjectivity, Identity and Penal Power: Incarceration in a Global Age"

Read More  

QMES (2013)

Quantum Mesoscopics with Vacuum Trapped Nanoparticles

Read More  

REFORM CAPACITY (2012)

The Reform Capacity of Governments

Read More